Ill. PRENATAL DIAGNOSIS PROGRAM
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The diagnosis of chromosomal and metabolic
abnorm alities by mid-trimester amniocentesis is now
an established part of antenatal care. Jacobson published the first use of this technique in 1967, 1 followed
in 1968 by Nadler. 2 By 1974, over 3,000 pregnancies
had been studied permitting the prenatal diagnosis of
a wide variety of chromosomal anomalies and more
than 60 different inborn errors of metabolism during
the second trimester of pregnancy at a time when
termination of the pregnancy can be safely performed
if an abnormality is detected . During this period, the
National Institute of Child Health and Human Development established a Nation al Registry for amniocentesis in an attempt to document the safety and
accuracy of this technique. Its report was published
in 1975 and dealt with a comparison of 1,040 pregnancies studied by mid-trimester amniocentesis and
992 matched control pregnancies.3 The conclusions
from the study were that mid-trimester amniocentesis
was a safe procedure when performed by a qualified
physician and that the accuracy rate of antenatal
genetic diagnosis was 99.4%. Since 1975, the use of
this procedure has become almost routine in pregnancies at risk for identifiable genetic abnormalities
because of maternal age or family history. It should
be emphasized that in the vast majority of cases prenatal genetic diagnosis is a life-saving procedure.
Many women who are at high risk would not choose
to continue their pregnancy unless they could be assured that there is no detectable fetal abnormality . In
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the series of 1,040 amniocentesis procedures mentioned above, only 34 abnorm alities were detected ; of
these, 27 women elected to terminate their pregnancy.
In addition, 11 male fetuses were identified among
the 21 at risk for X-linked disorders and 8 of these 11
women elected to terminate their pregnancies.
Because the number of qualified laboratories is
limited, the cases which can be studied must be restricted to certain high-risk categories. The largest
group of pregnant women at increased risk of producing an abnormal child are patients over 35 years
of age. It is well established th at as the mother ages ,
the incidence of nondisjunction in her gametes increases. Table I shows the relation between the incidence of trisomy 21 and maternal age. Another
indicator of the effect of maternal age is that while
only 13% of pregnancies occur in mothers over 35
years old , these pregnancies produce 51 % of all cases
of Down syndrome. Recent studies employing normal chromosomal markers 4 have clearly shown that
the extra chromosome in this syndrome is not invariably maternal in origin. If only those cases in
which the nondisjunction occurred in the mother
were considered, it seems likely that a more striking
relationship to the maternal age would be observed .
Age 35 is considered by many to be the maternal age
at which the risk is sufficiently great to recommend
amniocentesis, but this figure is obviously somewhat
arbitrary .
The second largest group of patients for whom
antenatal diagnosis is recommended are women who
have already had a child with trisomy 21 . The risk of
producing another mongoloid child in this group is
I% to 2%. Needless to say, these mothers are also
extremely anxious about a recurrence, and in most
cases the results of the cytogenetic _a nalysis serve to
all ay their fears.
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TABLE I
Relation of Maternal Age and Chromosome Abnormalities
Di stribution
of mothers
of children Risk of chromosome
Di stribution
with
abnormality by
o f tota l chromosome
age group
sa mple abnormality
Maternal
(%)
(%)
Age
N
Percentage

10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49

0.4
11.0
34.4
32.0
14.3
6.2
1.4
.07

0
5.3
42.4
21.2
5.3
21.2
5.3
0

0/ 19
1/ 490
8/ 1531
4/ 1423
1/ 635
4/ 277
1/ 62
0/ 3

0.20
0.52
0.28
0.16
1.44
1.61

Distributio n of materna l ages. N = number of abnormalities
di vided by number in age group.

A small group of patients at considerable risk for
chromosomally abnormal children are families in
which one of the parents carries a chromosomal
translocation . In these cases, the risk varies depending on the translocation . For example, in the case of a
t(2 l ;21) carrier, the risk of bearing a mongoloid child
is I 00%; while in the case of the more common DI G
translocation t( 15;2 l ), the risk of producing a child
with translocation Down syndrome varies from
about 10% to 30% depending upon whether the father
or the mother is the translocation carrier. This translocation group is responsible for "familial mongolism" and is fortunately quite rare . Of all mongoloid children, 2% to 3% are of the translocation type;
of these, only about half are familial and the remainder are de novo translocations.
Approximately 150 genetic diseases have been
recognized which show an X-linked pattern of transmission, and many such as the X-linked hemophilias,
Duchenne-type muscular dystrophy, and agammaglobulinemia are associated with serious or even
lethal disease . X-linked disorders only affect male
offspring, although carrier females may occasionally
show mild symptoms. Specific intrauterine diagnosis
is not yet possible for most X-linked traits; however,
since it is possible to diagnose the sex of the child in
utero, carrier females can avoid giving birth to additional affected males if they are willing to carry only
female infants to term . Some couples find this an
acceptable method of completing their families with-
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out the fear of a recurrent abnormality; others do
not. In any case the decision about whether or not to
use this approach is made by the parents themselves.
The dilemma of terminating potentially normal pregnancies would be solved if specific tests were available
to diagnose each X-linked disease. Currently, this is
possible only for a relatively few X-linked diseases in
which the specific enzymatic defect has been identified . These conditions include Hunter syndrome, the
Lesch-Nyhan syndrome, and Fabry disease. In addition, approximately 40 rare autosomal recession
traits are known in which the enzyme defect can be
detected with varying reliabilities in fibroblasts.
The last category of patients at risk for specific
fetal abnormalities are those who have had a previous
child with a neural tube defect (anencephaly, enccphalocele, meningomyelocele, and spin a bifida ). As a
group , the recurrence rate for any of these disorders
is about 5%. 5 These abnormalities are not chromosomal defects, therefore, the fetal karyotype is not
useful. However , it has been well proven that the level
of alph a-fetoprotein in the amniotic fluid at 16 to 18
weeks gestation correlates with these defects; a high
level of alpha-fetoprotein (greater than 5 standard
deviations above normal) is diagnostic of an open
neural tube defect. Amniography, fetoscopy, and ultrasound can also be utilized to document these abnormalities.
In summary, the general indications for amniocentesis for prenatal diagnosis are as follows:
I. Maternal age greater than 35 years at time of
conception.
2. History of a previous child with Down syndrome or any other trisomy .
3. Documented chromosomal translocation in
either parent.
4. Previous child with a serious inherited Xlinked disease or an autosomal genetic disease
that can be detected prenatally.
5. Previous child with a midline neurologic defect.
Table 2 is a summary of the indications for amniocentesis performed at MCV since 1973.
Patients who have been counseled and have a
definite indication for prenatal genetic diagnosis, and
who have given their informed consent, are first
scheduled for an ultrasound examination. This noninvasive scanning procedure can locate the placenta,
identify the best area for the amniocentesis, and rule
out twin gestations. It also accurately measures the
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TABLE 2

Indications for Prenatal Diagmisis at MCV
(9-1-73 to 7-1-77)
28
77
65
8
I

IO
22
I
2

I
2

Previou s trisom y 21
Maternal age 40 y r o r greater
Maternal age 35 yr to 39 yr
Close reiati ve with trisomy 21
Previous child with hemophili a A
Previou s spin a bifid a + cleft palate
Previou s spin a bifida or hydrocephalus or meningocele
Previo us anencephalic
Previous Potter sy ndrome
Anophthalmi a
Previo us G I G translocation carrier
Previous DI G tran slocation carrier
Elevated maternal creatine phosphokinase
Previous child with Sandhoff disease
Four previous spontaneous a bortions
Previous trisom y 18
Previous triso my 13
Previo4s XX / XO mosaics
Three previous "retarded" children
Previous child with "multiple defects"

fetal head to document fetal age. After the ultrasound
procedure, the patient's abdomen is prepared and
under sterile conditions the amniocentesis is performed by an experienced obstetrician. The amniocentesis procedure involves the introduction of a
small bore needle through the mother's abdominal
wall into the uterus and amniotic cavity under local
anesthesia. The ultrasound examination ilids in selecting the proper placement of the needle to avoid
the b<1by and to locate the amniotic fluid . Twenty
milliliters of fluid are withdrawn and the needle removed . Most patients have no ill effects from the
procedure and can go home shortly after it is performed . The optimum time to obtain the amniotic
fluid is from 15 to 16 weeks gestation .
Preliminary results are usually available within
three weeks of the procedure and the final report is
issued one to two weeks later.
Since most of the patients have a rate of below
5% of bearing an affected child, the results are usually
that the fetus has a normal chromosome complement. This greatly relieves the parents' anxiety and
allows them to have a happy prenatal course and
enjoy ;i normal baby. If, however, a mongoloid fetus
or a fetus with anencephaly is diagnosed, the parents
are counseled and pregnancy termination suggested.
This decision is left to the parents once the facts are
presented to them, and even for those parents who

TABLE 3
Medical College of Virginia Results of Antenatal Diagnosis
(9-1-73 to 7-1-77)
R ESULTS
92XXXX
46XY
46XX
45XY-D-G + DI G
45XO
47XY + G
47XX + G
47XXX
Normal alpha-fetoprotein
Abnormal alpha-fetoprotein

N UMBER

104
84
I
I

2

21
I

felt before the study that there would be no question
of terminating the pregnancy if the fetus were abnormal, the decision is a difficult one.
As of July I, 1977, at MCV, three patients, of
216 studied, have been diagnosed with trisomy 21 in
utero. All three patients underwent therapeutic abortion . In addition, the diagnosis of a fetus with Turner
syndrome (45XO) was made and the parents elected
to continue the pregnancy since the abnormality detected was not life-threatening. Table 3 summarizes
the results of the antenatal testing at MCV.
The future of antenatal genetic diagnosis is an
exciting one. Recent advances include the application
of chromosomal banding te~hniques to identify
subtle abnormalities and rearrangements; ultrasonography, using high resolution gray scale equipment
to permit delineation of fetal soft tissue and skeletal
anomalies; and fetoscopy , using a small fiberoptic
instrument to view the fetus directly and observe its
development. With the~e ad~ances in technology, it
should be possible to enable even more women at
high risk for genetically diseased offspring to bear
healthy children.
Table I is adapted from S cience (169:495-497, 1970).
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Recent Advances 1n Cytogenetic Technology
for Antenatal Genetic Testing
JUDITH A. BROWN, PH.D., ANNA CARR, ELIZABETH S. COOPER, AND
DEBORAH W. HERITAGE, Cytogenetic Laboratory, Department of Human Genetics

The examination of human chromosomes has
been a part of the physician's laboratory armamentarium since the correct diploid number of human
chromosomes was established' and a method was
developed 2 for the in vitro growth of peripheral blood
leukocytes to yield metaphase chromosomes. The
discovery3 that on ultraviolet microscopy (UV),
metaphase chromosomes stained with fluorochrome
dyes displayed a characteristic pattern of bright and
dull bands unique for a given pair of homologous
chromosomes, was a major technological breakthrough in huma n cytogenetics; for the first time,
every chromosome in the karyotype could be unequivocally identified . Although the short storage life
of fluorochrome-stained chromosomes and the costs
of UV microscopy have limited the usability of fluorescence banding, the introduction of one discriminating procedure quickly led to the development of an
array of similar banding techniques for conventional
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microscopy that yield comparable information. Some
of these technical procedures depend on enzyme and/
or heat denaturation of the chromosomes, resultiri~
in the characteristic banding patterns seen by the
trypsirt-Giemsa method, 4 the 5M urea method,5 and
the acid-saline-Giemsa technique.6 A typical human
karyotype prepared from metaphase chromosomes
treated with trypsin, stained with Giemsa, and photographed with brightfield photomicrographic techniques is shown in Figure I. Careful examination of
this karyotype reveals that each chromosome in the
homologous pair has an array of dark and light
bands identical with those of its homolog and that
each homologous pair, autosomes number I to number 22, has a characteristic, easily identifiable ba nding pattern.
In order to establish a standardized nomenclature to describe the chromosomes and chromosome
regions, as revealed by the banding techniques, a
committee of intern ational experts in human cytogenetics met in Parls, France, in 1971. 7 The committee retained the previously established designation
of the short arm of the chromosome as "p" and the
long arm as "q" and agreed to divide the chromosome arms into a number of regions according to the

